OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

NCT ID: NCT06560476

Last Updated: 2026-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-30

Study Completion Date

2027-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Arm

This is the data collection study arm. There is no other arm in the study.

Data collection

Intervention Type OTHER

Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Patients treated with the Optilume BPH Catheter System in accordance with the Instructions for Use (IFU).

Exclusion Criteria

1. Unwilling to abstain from sexual intercourse or use a condom for 30 days post-procedure and utilize a highly effective contraceptive for at least 12 months post-procedure
2. Presence of an artificial urinary sphincter, penile prosthesis, or stent(s) in the urethra or prostate
3. Confirmed or suspected malignancy of prostate or bladder.
4. Active urinary tract infection (UTI)
5. Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System
Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Urotronic Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Golden State Urology

Sacramento, California, United States

Site Status WITHDRAWN

Florida Urology Partners

Tampa, Florida, United States

Site Status RECRUITING

Kearney Urology Center

Kearney, Nebraska, United States

Site Status RECRUITING

The Urology Center, P.C.

Omaha, Nebraska, United States

Site Status COMPLETED

Sheldon Freedman, Ltd

Las Vegas, Nevada, United States

Site Status RECRUITING

Northwell Health - Smith Institute of Urology

Syosset, New York, United States

Site Status RECRUITING

Good Samaritan Hospital

Corvallis, Oregon, United States

Site Status COMPLETED

Midtown Urology

Austin, Texas, United States

Site Status RECRUITING

Potomac Urology

Woodridge, Virginia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kaitlyn Palm

Role: CONTACT

6128160068

Reem Ennenga

Role: CONTACT

61274741836

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jodi Mummert

Role: primary

813-431-4913

Alejandra Valdes

Role: backup

813-764-7147

Garrett Pohlman, MD

Role: primary

303-249-7570

Omar Darwish

Role: primary

702-732-0282

Danielle Freedman

Role: backup

7027320282

Jennifer Polo

Role: primary

5167603980

Andrew Barger

Role: primary

5124517935

Morgan Gray

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PR1326

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.